Description General description A cell-permeable, reversible, ATP-competitive, and selective inhibitor of platelet-derived growth factor (PDGF) receptor kinase (IC50 = 500 nM) and PDGF-dependent DNA synthesis (IC50 = 2.5 µM) in Swiss/3T3 cells. Has no effect on EGF receptor autophosphorylation and shows only a weak effect on EGF- or insulin-stimulated DNA synthesis. A potent blocker of smooth muscle cell proliferation. Selectively inhibits platelet-derived growth factor (PDGF) receptor kinase (IC50 = 500 nM) and the PDGF-dependent DNA synthesis (IC50 = 2.5 µM) in Swiss 3T3 cells. Has no effect on epidermal growth factor (EGF) receptor autophosphorylation and shows only a weak effect on EGF- or insulin-stimulated DNA synthesis. Packaging 5 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: yes Primary Target PDGFR kinase Product competes with ATP. Reversible: yes Target IC50: 500 nM against PDGFR kinase Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C. Other Notes Banai, S., et al. 1998. Circulation 97, 1960. Levitzki, A., and Gazit, A. 1995. Science267, 1782. Kovalenko, M., et al. 1994. Cancer Res.54, 6106.